Fact-checked by Grok 2 weeks ago

Complementarity-determining region

Complementarity-determining regions (CDRs) are hypervariable sequences located within the variable domains of immunoglobulins (antibodies) and T-cell receptors (TCRs), forming the structural basis for and specific binding in the adaptive . These regions exhibit high sequence diversity due to and , enabling the to generate a vast repertoire of specificities against diverse pathogens and foreign molecules. In antibodies, each consists of six CDRs—three in the heavy chain (H1, H2, H3) and three in the light chain (L1, L2, L3)—that collectively create a complementary to the 's . Similarly, TCRs feature six CDRs (three each in the α and β chains), where CDR1 and CDR2 primarily interact with (MHC) molecules, while CDR3 loops provide peptide-specific contacts. The structural diversity of CDRs arises from their loop conformations, with most adopting canonical structures determined by germline sequences, except for the highly variable CDR3 regions generated by V(D)J recombination. This variability is crucial not only for antigen specificity but also for additional functions, such as direct antimicrobial, antiviral, and antitumor activities independent of full antibody context. Numbering schemes like Kabat, Chothia, and IMGT standardize CDR identification across sequences, aiding in antibody engineering and therapeutic design, though differences in definitions highlight ongoing refinements in structural immunology. Overall, CDRs exemplify the precision of immune recognition, underpinning applications in monoclonal antibodies, CAR-T therapies, and vaccine development.

Definition and Nomenclature

Definition

Complementarity-determining regions (CDRs) are hypervariable polypeptide segments located within domains of immunoglobulins (antibodies) and T-cell receptors (TCRs), characterized by high that enables specific of antigens. These regions were first identified based on their elevated variability in sequences compared to other parts of the variable domains. In contrast to CDRs, the intervening framework regions (FRs) exhibit greater sequence conservation and form a beta-sheet structural scaffold that supports the positioning of the CDRs. Each variable domain contains three CDRs, designated CDR1, CDR2, and CDR3, which together contribute to the antigen-binding functionality. In antibodies, the —the antigen-binding site—is formed by the six CDRs from the and heavy chains (three from each), creating a complementary surface for interaction. This arrangement results in six CDRs per fragment and twelve CDRs in a full IgG antibody molecule, which consists of two arms. The hypervariability of CDRs is a critical feature that underpins specificity in adaptive immunity. Evolutionarily, CDRs have been conserved across members as essential elements driving the diversity required for broad immune recognition.

Numbering Systems

The Kabat numbering system, developed in the , provides a foundational framework for identifying complementarity-determining regions (CDRs) based on sequence variability in variable domains. It assigns residue positions sequentially, starting from the of the variable domain, with CDRs defined as hypervariable segments. For the light chain, CDR-L1 spans positions 24-34, CDR-L2 positions 50-56, and CDR-L3 positions 89-97; for the heavy chain, CDR-H1 covers 31-35, CDR-H2 50-65, and CDR-H3 95-102. This system prioritizes regions of high sequence diversity observed in early alignments of Bence Jones proteins and myeloma light chains, facilitating the annotation of conserved framework regions (FRs) alongside variable loops. The Chothia numbering scheme, introduced in , refines the Kabat approach by incorporating structural data from to emphasize the conformations of CDR loops. It adjusts insertion points and boundaries to align with canonical loop structures, particularly in CDR-H1 (26-32) and CDR-H2 (52-56), while maintaining similar definitions for light chain CDRs as in Kabat (L1: 24-34, L2: 50-56, L3: 89-97) and heavy chain CDR-H3 (95-102). This structural focus ensures that equivalent positions across antibodies correspond to topologically similar sites in the three-dimensional fold, aiding in the prediction of loop geometries. The IMGT numbering system, established by the International ImMunoGeneTics information system in the late 1990s and formalized in 2003, offers a unified, species-independent scheme for immunoglobulin and genes. It uses a standardized of variable domain sequences, with positions marked by colons for insertions (e.g., 27.1, 27.2), and defines CDRs as follows: CDR1 (27-38), CDR2 (56-65), and CDR3 (105-117) for both light and heavy chains. This approach integrates sequence, structure, and genetic data, enabling consistent annotation across diverse immune repertoires. These systems differ in their foundational principles: Kabat emphasizes sequence hypervariability, Chothia prioritizes of loops, and IMGT provides an integrative for genomic and proteomic databases. For instance, Kabat may include more framework residues in CDRs due to its variability-based boundaries, while Chothia and IMGT better capture conformationally equivalent positions but can vary in insertion handling. A comparison of CDR boundaries across the schemes is shown below:
ChainCDRKabat PositionsChothia PositionsIMGT Positions
Light124-3424-3427-38
Light250-5650-5656-65
Light389-9789-97105-117
Heavy131-3526-3227-38
Heavy250-6552-5656-65
Heavy395-10295-102105-117
In practice, these numbering systems are essential for , enabling automated annotation and querying in immunoinformatics tools. For example, the IMGT/V-QUEST platform uses IMGT numbering to identify CDR boundaries, detect mutations, and classify variable genes in user-submitted sequences from diverse species. Such tools support repertoire sequencing studies and antibody engineering by standardizing data across datasets.

Structure and Location

Location in Variable Domains

Complementarity-determining regions (CDRs) reside within the variable domains of antibodies and T-cell receptors (TCRs). In antibodies, these domains consist of the VL region on the light chain and the region on the heavy chain, each containing three CDRs (L1–L3 and H1–H3, respectively). Similarly, in αβ TCRs, CDRs are positioned in the Vα and Vβ domains, with three loops per chain (CDR1α–3α and CDR1β–3β) that parallel the antibody arrangement. These variable domains feature an immunoglobulin fold characterized by two antiparallel β-sheets forming a sandwich-like structure, with the CDRs emerging as loops from one surface of this framework. CDR1 and CDR2 are situated between the β-strands (specifically connecting strands B–C for CDR1 and C′–C″ for CDR2 in standard notation), while CDR3 connects strands F–G, positioning it at the C-terminal end of the variable domain. This topographic distribution positions the CDRs in close spatial proximity on the domain surface, enabling coordinated interactions. The boundaries of these loops can be assigned using numbering schemes like Kabat, which delineate CDR positions based on sequence variability. In the Fab region of antibodies, the CDRs from VL and VH domains converge at the inter-domain interface, collectively shaping a binding pocket for recognition. Light chain CDRs are typically shorter (e.g., L1: ~10–17 residues, L2: ~7 residues, L3: ~9–11 residues), whereas heavy chain CDRs exhibit greater length variation, with CDR-H3 often extending 5–45 residues and displaying the highest diversity due to its role in junctional recombination. This disparity enhances the structural flexibility and specificity of the . Crystal structures, such as PDB entry 1IGT of an intact IgG2a , visualize these CDR positions protruding from the β-sheet frameworks of VL and .

Loop Conformations and Canonical Structures

Complementarity-determining region (CDR) loops exhibit significant flexibility in their three-dimensional conformations, which are crucial for forming the antigen-binding site on antibody variable domains. CDR1 and CDR2 loops are typically shorter, ranging from 5 to 17 residues in length, while CDR3 loops are longer, often spanning 3 to 25 or more residues, and tend to adopt more extended conformations due to their variability. The concept of canonical structures classifies these loop conformations based on their amino acid sequence, particularly loop length, backbone phi/psi angles, and key residue identities at specific positions. Introduced by Chothia and colleagues in , this identifies discrete classes of structures for CDR1, CDR2, and light-chain CDR3 loops, with examples including 5 canonical classes for light-chain CDR1 (L1) and 3 for heavy-chain CDR2 (H2). These structures are predominantly determined by germline-encoded sequences in CDR1 and CDR2, ensuring a limited repertoire of conformations despite sequence diversity. Conformational determinants extend beyond the CDRs themselves, with framework region residues playing a pivotal role in stabilizing loop shapes. For instance, residues at positions 71 and 93 in the heavy-chain variable domain () can influence the orientation and rigidity of adjacent CDR loops, as demonstrated in studies of humanization where framework substitutions altered loop conformations. This interplay ensures that CDR1 and CDR2 maintain their canonical forms, which are often conserved across immunoglobulin structures. In contrast, CDR3 loops, particularly in the heavy chain (H3), lack defined canonical classes owing to extensive junctional diversity during V(D)J recombination, leading to highly variable sequences and lengths. These loops frequently form extended or irregular structures, such as beta-hairpins or kinked conformations, rather than the more rigid classes seen in other CDRs. Structural analyses of immunoglobulin loops from the Protein Data Bank (PDB) have further refined these classifications. Al-Lazikani et al. (1997) cataloged standard conformations for canonical structures in L1, L2, L3, H1, and H2 loops across 17 antibody structures, showing that most (71 out of 85 hypervariable regions) closely match predefined standards, underscoring the predictability of non-H3 loops while highlighting H3's unique diversity.

Generation and Diversity

Genetic Recombination

V(D)J recombination is the primary somatic genetic process that assembles variable region genes encoding the complementarity-determining regions (CDRs) in immunoglobulins and T cell receptors (TCRs) during lymphocyte development in the bone marrow and thymus, respectively. This enzymatic mechanism involves the precise cutting and joining of variable (V), diversity (D, for heavy chains and TCR β/δ), and joining (J) gene segments, guided by recombination signal sequences (RSSs) that flank each segment and adhere to the 12/23 rule for compatibility. The process is initiated by the lymphocyte-specific recombination-activating genes RAG1 and RAG2, which form a complex that recognizes RSSs, introduces double-strand breaks, and recruits non-homologous end joining (NHEJ) repair machinery—including DNA-PK, Ku, Artemis, and ligase IV—to ligate the segments. In B cells, this generates diverse B cell receptor (BCR) genes, while in T cells, it assembles TCR genes, establishing the foundational antigen recognition repertoire without reliance on somatic hypermutation. The CDRs are directly shaped by V(D)J recombination, with CDR1 and CDR2 encoded entirely within the V gene segment, providing a framework for antigen contact, whereas CDR3 is formed at the V-D and D-J junctions, incorporating hypervariable sequences critical for specificity. For immunoglobulin loci, the heavy chain (IGH) on chromosome 14 includes 38-46 functional V_H segments, 23 D_H segments, and 6 J_H segments, allowing combinatorial joining that contributes to heavy chain diversity. Light chain loci lack D segments: the kappa (IGK) locus on chromosome 2 has 34-38 functional V_κ and 5 J_κ segments, while the lambda (IGL) locus on chromosome 22 features 29-33 functional V_λ and 4-5 J_λ segments. TCR loci follow a parallel organization; for example, the TCRα locus on chromosome 14 has 43-45 functional V_α and 50 J_α segments for V-J joining, the TCRβ locus on chromosome 7 includes 40-48 functional V_β, 2 D_β, and 12-13 J_β segments, the TCRγ locus has 4-6 functional V_γ and 5 J_γ clusters, and the TCRδ locus (nested within TCRα) contains 3 functional V_δ (7-8 including shared TRAV/DV), 3 D_δ, and 4 J_δ segments. These segmental combinations alone yield millions of possible variable domains, amplified further by junctional modifications. Junctional diversity at the V-D-J boundaries vastly expands CDR3 variability, primarily through exonuclease-mediated trimming of segment ends, addition of palindromic (P) nucleotides from hairpin resolution during cleavage, and random nontemplated (N) nucleotide insertions by terminal deoxynucleotidyl transferase (TdT), which is highly expressed in pro-lymphocytes. These processes can add or delete up to 15 or more nucleotides per junction, creating up to 10^6 potential CDR3 sequences per combinatorial join, with heavy chain CDR3 particularly diverse due to dual V-D and D-J junctions. Overall, V(D)J recombination enables a theoretical antibody repertoire exceeding 10^11 unique specificities in humans, combining segmental choice, junctional flexibility, and light-heavy chain pairing. This mechanism is evolutionarily conserved across jawed vertebrates, from cartilaginous fish to mammals, where RAG-mediated V(D)J recombination generates adaptive immune receptor diversity essential for pathogen recognition. In all such species, the core enzymatic machinery and RSS-directed joining ensure comparable repertoire generation, though segment numbers and locus organization vary.

Somatic Hypermutation and Affinity Maturation

Somatic hypermutation (SHM) is a secondary diversification mechanism that refines the antibody repertoire after initial V(D)J recombination by introducing point mutations into the variable regions of immunoglobulin genes, primarily in activated B cells within germinal centers. This process is initiated by activation-induced cytidine deaminase (AID), an enzyme that deaminates cytosine residues to uracil in single-stranded DNA, leading to mutations at a rate of approximately 10^{-3} per base pair per generation—about a million times higher than the spontaneous genomic mutation rate. AID activity is preferentially targeted to the complementarity-determining regions (CDRs) of the variable domains, where mutations are more frequent than in the framework regions (FRs), enhancing the potential for improved antigen binding without disrupting overall structure. SHM exhibits a biased mutation spectrum, with hotspots defined by the RGYW/WRCY motifs (where R = A or G, Y = C or T, W = A or T), which account for a significant portion of s due to AID's preference for these sequences on both DNA strands. These motifs are enriched in CDRs compared to FRs, contributing to the higher mutability observed in antigen-contacting loops; for instance, replacement s in CDRs occur at rates 1.5–2 times higher than in FRs across various immunoglobulin genes. Among the CDRs, CDR3 experiences the most extensive due to its inherent length variability and junctional from recombination, allowing for greater evolutionary exploration of binding interfaces. Affinity maturation couples SHM with Darwinian selection in germinal centers, where B cells iteratively mutate their immunoglobulin genes and compete for presented on . B cells bearing CDRs with mutations that enhance receive survival signals from T follicular helper cells, leading to preferential proliferation and differentiation, while lower-affinity clones undergo . This cyclic process in the germinal center's dark and light zones refines CDR sequences over multiple generations, often concentrating beneficial mutations in the CDRs to optimize geometry. The cumulative effect of SHM and affinity maturation dramatically boosts performance, typically increasing binding affinity by 100- to 1000-fold through selected mutations that strengthen key interactions with antigens. This refinement is essential for generating high-specificity antibodies capable of effective neutralization and immune memory.

Function and Binding

Antigen Recognition Mechanism

The antigen recognition mechanism of complementarity-determining regions (CDRs) relies on the structural complementarity between the —the binding surface formed primarily by the six CDR loops—and the , enabling precise molecular docking through non-covalent interactions. This complementarity involves both shape and electrostatic matching, where the paratope molds to the epitope's contours via mechanisms such as induced fit, in which binding triggers conformational adjustments in the CDRs, or conformational selection, where the stabilizes a pre-existing CDR conformation from an ensemble of states. The interactions are predominantly non-covalent, encompassing hydrogen bonds, van der Waals forces, and electrostatic attractions, often mediated by water molecules at the interface; these forces collectively bury a substantial portion of the solvent-accessible surface area, typically around 1000–2000 Ų in total across both partners in the complex, fostering stability without covalent linkage. Among the CDRs, contributions to contacts vary, with CDR-H3 (heavy chain CDR3) playing a dominant role due to its hypervariability and central positioning, often accounting for the majority of direct interactions and penetrating deeply into the . In contrast, CDR-L3 (light chain CDR3) and CDR-H2 provide key specificity by framing the binding pocket and engaging peripheral regions, while CDR-H1 and the light chain CDRs 1 and 2 offer supplementary support. Not all CDR residues participate equally; structural analyses indicate that only about 20–33% of CDR atoms typically form contacts, emphasizing the focused nature of recognition. In B-cell receptors (BCRs, equivalent to antibodies), CDRs recognize native, conformational epitopes on diverse antigens such as proteins or haptens in a direct manner, allowing broad specificity. By comparison, T-cell receptors (TCRs) employ a distinct strategy, contacting peptide-MHC complexes where CDR1 and CDR2 primarily interact with the conserved MHC helices for docking, while the more variable CDR3 loops focus on the embedded peptide antigen to confer specificity. This dichotomy reflects evolutionary adaptations for humoral versus cellular immunity. Experimental validation of these mechanisms comes from of -antigen complexes, such as the HyHEL-10 bound to hen egg lysozyme, which reveals loops, particularly CDR-H3, penetrating the antigen's cleft and forming extensive hydrogen bonds and van der Waals contacts that bury significant surface area. Similar structures, like HyHEL-5-lysozyme (PDB ID: 1HHL), demonstrate induced fit adjustments in conformations upon , underscoring the dynamic nature of recognition.

Affinity and Specificity Determinants

The of antibody-antigen binding, quantified by the K_d, typically ranges from the nanomolar () to picomolar () scale for high-affinity interactions, reflecting binding energies around 12 kcal/ for K_d \approx 1 . This is primarily determined by the composition of residues in the complementarity-determining regions (CDRs), where aromatic such as (Tyr) and (Trp) play a central role by forming bonds and engaging in aromatic stacking interactions with the . These residues constitute about 53% of the functional atoms in CDRs, enabling stable non-covalent contacts that enhance binding strength. Specificity in CDR-mediated recognition arises from shape complementarity between the and , with the shape complementarity value (S_c) averaging 0.64–0.68 for antibody-protein complexes, though values up to 0.78–0.82 occur in optimized cases with minimal buried molecules. Electrostatic matching further refines selectivity, as over 80% of polar contacts in CDRs are electrostatically favorable, with approximately 40% forming direct bonds involving polar residues like serine (Ser) and (Asn). The length and depth of CDR loops, particularly CDR3, tune the to fit specific pockets, with CDR3 often dictating fine specificity due to its hypervariability and central positioning in the . Hydrophobic residues in CDRs contribute to core packing and van der Waals interactions, comprising 14–17% of contacts, while short-chain hydrophilic residues surround aromatic cores to prevent nonspecific binding. In multimeric immunoglobulins like IgM, which features 10 antigen-binding sites, multivalency amplifies overall through simultaneous CDR engagements, compensating for individually lower-affinity interactions and enhancing effective specificity against multiepitope targets. Environmental factors such as and modulate affinity; for instance, acidic conditions can disrupt histidine-mediated interactions in CDRs, increasing K_d by altering states, while elevated temperatures weaken hydrophobic contacts. refines these determinants by introducing mutations that increase hydrophobic solvent-exposed surfaces in CDRs, optimizing packing and boosting affinity without compromising specificity.

Applications in Immunology and Biotechnology

Role in Adaptive Immunity

Complementarity-determining regions (CDRs) are integral to , where B-cell-derived antibodies utilize these hypervariable loops to bind specific epitopes on pathogens, thereby facilitating neutralization by blocking viral entry or toxin activity and opsonization by marking targets for . The six CDRs—three each from the heavy and light chains—form the antigen-binding site, enabling precise recognition that underpins antibody-mediated protection against infections. This binding specificity allows antibodies to neutralize diverse pathogens, such as viruses, by preventing their attachment to host cells, while opsonization enhances clearance through engagement on immune cells. In cellular immunity, CDRs within T-cell receptors (TCRs) play a crucial role by recognizing peptide antigens presented by (MHC) molecules, triggering T-cell activation and cytotoxic responses. TCR CDR loops, particularly CDR3, contact both the peptide and MHC surfaces, ensuring and specificity in distinguishing self from non-self. This interaction initiates downstream signaling for T-cell proliferation, cytokine release, and elimination of infected or aberrant cells, complementing humoral mechanisms in adaptive immunity. The diversity of CDRs drives repertoire dynamics, distinguishing naive B and T cells, which possess germline-encoded sequences covering a broad but unrefined range, from memory cells shaped by antigen exposure and somatic hypermutation for higher affinity. CDR variability, generated through V(D)J recombination and junctional modifications, enables the immune repertoire to recognize an estimated ~10^8 distinct epitopes across potential pathogens, ensuring comprehensive coverage in naive states while memory cells refine responses for rapid recall. This vast diversity supports long-term immunity by adapting to evolving threats without prior exposure. Evolutionarily, CDRs emerged in jawed vertebrates (gnathostomes) as part of the immunoglobulin and TCR systems, relying on RAG-mediated recombination for diversity, and are conserved across this to enable adaptive . In contrast, agnathans (jawless vertebrates like lampreys and ) lack CDRs, instead using variable receptors (VLRs) based on leucine-rich repeats for binding via a distinct conversion mechanism. Pathologically, mutations in CDRs can contribute to ; for instance, mutations in rheumatoid factor CDRs enhance binding to self-IgG Fc regions, promoting chronic inflammation in . Such alterations disrupt , leading to autoreactive antibodies that drive damage.

Engineering and Therapeutic Design

Complementarity-determining regions (CDRs) are frequently engineered through CDR grafting, a technique that transfers CDRs from non-human antibodies into human framework regions to minimize while preserving antigen-binding specificity. This approach, first demonstrated in 1986 by grafting mouse CDRs into a human myeloma protein framework, resulted in an antibody that retained comparable affinity (1.9 µM versus 1.2 µM original), enabling the production of therapeutic monoclonal antibodies suitable for human use. For instance, humanized variants of rituximab, an anti-CD20 antibody, have been developed via CDR grafting onto human germline frameworks, reducing potential immune responses while maintaining tumor cell-binding efficacy and in preclinical models. De novo design of CDR loops leverages computational tools to create novel specificities, often starting from antigen structures and optimizing loop conformations for high-affinity binding. The RosettaAntibodyDesign (RAbD) protocol, for example, employs a two-stage Monte Carlo optimization to graft canonical CDR templates and refine sequences, achieving improved affinities in experimental validations across antibody-antigen complexes. More recently, AI-driven methods like RFdiffusion generate atomically accurate CDR structures (RMSD 0.2–1.1 Å for scFv CDRs), with subsequent affinity maturation yielding sub-nanomolar binders, such as a VHH against refined 100-fold from 260 nM. In therapeutic monoclonal antibodies like , engineered CDRs—particularly in the heavy chain—contribute critically to HER2 recognition, as revealed by cryo-EM structures showing preserved binding interfaces in bispecific formats. Bispecific antibodies further exploit CDR engineering by incorporating dual specificities, such as in HER2xHER3 formats that target complementary pathways to overcome , or biparatopic designs linking adjacent HER2 molecules for enhanced . However, challenges persist, including CDR-framework (FR) incompatibility that can impair expression and —addressed by matrixed across multiple human frameworks, where >60% VL retains 91% activity—and CDR3 instability, which often reduces thermal due to sequence-framework mismatches. Advances in , such as generative models like IgGM for CDR sequence , and CRISPR-based enable precise in situ modification of heavy-chain CDR3 regions in primary B cells, achieving ~1% efficiency for HIV-neutralizing reprogramming with potential for in vivo therapeutic diversification.

References

  1. [1]
  2. [2]
  3. [3]
    Antibody Structure and Function: The Basis for Engineering ...
    As shown in Figure 3, each domain contributes three complementarity-determining regions CDR-L1, CDR-L2, and CDR-L3 for VL and CDR-H1, CDR-H2, and CDR-H3 for VH.<|control11|><|separator|>
  4. [4]
    Understanding the Significance and Implications of Antibody ...
    This review compares and discusses the different numbering schemes and “CDR” definition that were established up to date.
  5. [5]
    Unusual distributions of amino acids in complementarity ... - PubMed
    Unusual distributions of amino acids in complementarity-determining (hypervariable) segments of heavy and light chains of immunoglobulins and their possible ...
  6. [6]
  7. [7]
    A potential antibody repertoire diversification mechanism through ...
    Dec 8, 2022 · The paratope at these six CDRs from HC and LC determines antibody's binding affinity and specificity to the epitope on the antigens. The ...
  8. [8]
    Immunoglossary - Jackson ImmunoResearch
    An IgG antibody has 12 CDRs, with two Fab Fragments comprising three CDRs on each of the heavy and light chains. *A heavy chain-only antibody, found in ...
  9. [9]
    Characterizing immune repertoires by high throughput sequencing
    HTS and analysis of antigen receptor repertoires can be used to characterize key features of adaptive immunity, such as repertoire diversity, clonal expansion, ...Lymphocyte Antigen Receptors... · Data Processing And Analysis · Antigen Receptor Repertoire...
  10. [10]
    AN ANALYSIS OF THE SEQUENCES OF THE VARIABLE REGIONS ...
    AN ANALYSIS OF THE SEQUENCES OF THE VARIABLE REGIONS OF BENCE JONES PROTEINS AND MYELOMA LIGHT CHAINS AND THEIR IMPLICATIONS FOR ANTIBODY COMPLEMENTARITY.
  11. [11]
    Understanding the Significance and Implications of Antibody ... - NIH
    Kabat and Wu postulated that these hypervariable regions would cluster at one side of the folded domain to form a surface responsible for specific antigen ...
  12. [12]
    50 Years of Antibody Numbering Schemes: A Statistical and ... - NIH
    Comparison of CDR numbering schemes of variable regions defined using Kabat, Chothia, Consensus Chothia, AbM, and IMGT methods. General CDRs are defined to ...
  13. [13]
    Antibody Complementarity-Determining Regions (CDRs) Can ... - NIH
    Jun 11, 2008 · Complementarity-determining regions (CDRs) are immunoglobulin (Ig) hypervariable domains that determine specific antibody (Ab) binding.
  14. [14]
    Subtle changes at the variable domain interface of the T-cell ... - NIH
    Three of the CDRs are encoded by the variable region domain of one chain, and three of the CDRs are encoded by the variable region domain of the other chain. ...
  15. [15]
    Antibody Structure and Function: The Basis for Engineering ... - MDPI
    In the two domains, the CDRs are composed of amino acid residues in the loops connecting the framework β-strands ↑B and ↓C for CDR-L1 and CDR-H1, ↑C' and ↓C'' ...
  16. [16]
    Antibody numbering schemes: advances, comparisons and tools for ...
    Building upon the original Chothia scheme, Martin introduces various corrections and refinements based on detailed structural analyses and comparisons with ...
  17. [17]
    Complementarity Determining Region - ScienceDirect.com
    (B) When the Ig molecule folds into its native conformation (only the Fab region is shown), the CDRs are grouped together to form an antigen-binding region that ...
  18. [18]
    A window into the human immune system - NIH
    Oct 24, 2023 · Length distribution of human immunoglobulin heavy and light chain CDRs. a) CDRH1. 80,1% of the sequences fall under a CDRH1 length of 8 ...
  19. [19]
    1IGT: STRUCTURE OF IMMUNOGLOBULIN - RCSB PDB
    Jul 7, 1997 · Refined structure of an intact IgG2a monoclonal antibody. · Total Structure Weight: 148.68 kDa · Atom Count: 10,434 · Modeled Residue Count: ...
  20. [20]
    Canonical structures for the hypervariable regions of immunoglobulins
    We have analysed the atomic structures of Fab and VL fragments of immunoglobulins to determine the relationship between their amino acid sequences and the ...Missing: loops | Show results with:loops
  21. [21]
    Canonical structures for the hypervariable regions of ...
    Canonical structures for the hypervariable regions of immunoglobulins. · C. Chothia, A. Lesk, +1 author. A. Lesk · Published in Journal of Molecular Biology 20 ...
  22. [22]
    Humanization of a mouse monoclonal antibody by CDR-grafting
    Using a molecular model of the mouse mAb 425 variable regions, framework residues (FRs) that might be critical for antigen-binding were identified.
  23. [23]
    Standard conformations for the canonical structures of ... - PubMed
    A comparative analysis of the main-chain conformation of the L1, L2, L3, H1 and H2 hypervariable regions in 17 immunoglobulin structures ...Missing: CDR PDB
  24. [24]
    [PDF] Standard Conformations for the Canonical Structures of ...
    Standard Conformations for the Canonical Structures of Immunoglobulins. Bissan Al-Lazikani, Arthur M. Lesk and Cyrus Chothia. MRC Laboratory of Molecular.
  25. [25]
    The generation of diversity in immunoglobulins - NCBI - NIH
    The molecular mechanism of V-region DNA rearrangement, or V(D)J recombination, is illustrated in Fig. 4.7. The 12 bp spaced and 23 bp spaced RSSs are ...
  26. [26]
    T-cell receptor gene rearrangement - Immunobiology - NCBI Bookshelf
    The arrangement of the gene segments resembles that at the immunoglobulin loci, with separate variable (V), diversity (D), joining (J) gene segments, and ...
  27. [27]
    Exonuclease activity and P nucleotide addition in the generation of ...
    Sep 2, 2004 · Junctional diversity results from the loss of nucleotides through the action of unknown exonuclease(s) and from the addition of N [3] and P ...
  28. [28]
    New insights into the evolutionary origins of the RAG proteins and V ...
    The adaptive immune system of jawed vertebrates relies on V(D)J recombination as one of the main processes to generate the diverse array of receptors necessary ...
  29. [29]
    Somatic hypermutation of the AID transgene in B and non-B cells
    SHM causes point mutations and occasional deletions and insertions at very high rates of ≈10−3 bp per generation and occurs during the centroblast stage of B ...<|control11|><|separator|>
  30. [30]
    DNA Damage Responses During Somatic Hypermutation - PubMed
    Mar 12, 2019 · The mutation rate of this programmed mutagenesis is ~10-3 base pairs per generation, a million-fold higher than the non-AID targeted genome ...
  31. [31]
    Genetic Plasticity of V Genes Under Somatic Hypermutation - NIH
    We find that the average replacement mutability of a CDR nucleotide in VH6-1 is 1.6 times higher than the average replacement mutability of a FR nucleotide, ...
  32. [32]
    targeting of RGYW motifs on both DNA strands - PubMed - NIH
    These results indicate that the mutational machinery targets RGYW sequences for mutations on either DNA strand and do not support the contention that the ...
  33. [33]
    Mesoscale DNA feature in antibody-coding sequence facilitates ...
    May 11, 2023 · The in vitro AID deamination profiles revealed higher mutability in CDRs than in FRs at all C/G (Figure 1G) and the WRC motifs (Figure 1H). Next ...
  34. [34]
    Different Somatic Hypermutation Levels among Antibody ... - Frontiers
    IgH-CDR3 has been reported to be shorter in highly mutated Ig than non-mutated Ig (29). During maturation of B cells, a small portion of IgM with shorter CDR3 ...
  35. [35]
    Review Germinal Center B Cell Dynamics - ScienceDirect.com
    Sep 20, 2016 · Affinity maturation happens in cycles of proliferation and SHM in the DZ followed by antigen-driven selection in the LZ.Missing: CDR | Show results with:CDR
  36. [36]
    Taking Advantage: High Affinity B cells in the Germinal Center ... - NIH
    It could be that higher affinity cells proliferate more rapidly or are more likely to enter cell cycle, thereby outgrowing lower affinity cells. Alternatively, ...
  37. [37]
    Recycling of memory B cells between germinal center and lymph ...
    May 5, 2022 · Affinity maturation of B cells occurs via molecular evolution in germinal centers (GCs). This involves cycles of B cell proliferation and the ...Missing: CDR | Show results with:CDR
  38. [38]
    How Low-Affinity Antibodies Produced Early in Immune Responses ...
    May 1, 2014 · ... orders of magnitude higher affinity for that antigen. These changes, often termed affinity maturation, take place largely in small B-cell ...
  39. [39]
    The Structural Basis of Antibody-Antigen Recognition - PMC - NIH
    The six hypervariable loops within the variable domains of Abs, commonly termed complementarity determining regions (CDRs), are widely assumed to be responsible ...
  40. [40]
  41. [41]
  42. [42]
    Comparative Analysis of the CDR Loops of Antigen Receptors
    For both proteins, the main determinants of target recognition are the complementarity-determining region (CDR) loops. Five of the six CDRs adopt a limited ...
  43. [43]
  44. [44]
  45. [45]
    Origins of specificity and affinity in antibody–protein interactions
    The predicted hot spot paratope residues (with PPI_CL ≥ 0.45 or proABC_CP ≥ 80%; see previous section) have been further validated by the threshold of dSASA ≥ ...
  46. [46]
    Structural basis of activation-dependent binding of ligand-mimetic ...
    However, the interface's shape complementary index (Sc value) is 0.78, significantly higher than the average antibody/antigen value of 0.66 (17), and is ...
  47. [47]
    Diversity in the CDR3 Region of VH Is Sufficient for Most Antibody ...
    These results are consistent with a model in which the highly diverse CDR3 loops are the key determinant of specificity in antigen recognition in both T cell ...
  48. [48]
  49. [49]
    Efficient affinity maturation of antibody variable domains requires co ...
    Mar 28, 2017 · Interestingly, sequences of diverse human antibodies that have undergone somatic hypermutation show shifts toward increased hydrophobic solvent- ...
  50. [50]
    Recent advances in therapeutic applications of neutralizing ...
    Nov 8, 2020 · Antibodies are considered as an excellent foundation to neutralize pathogens and as highly specific therapeutic agents.
  51. [51]
    The basis for limited specificity and MHC restriction in a T cell ...
    Jun 5, 2013 · Recognition of peptide antigens by the αβ T cell receptor (TCR) underlies cellular immunity. TCRs recognize peptides bound and presented by ...
  52. [52]
    On defining the rules for interactions between the T cell receptor and ...
    The striking concentration of TCR diversity in the CDR3 loops has led to the proposal that the CDR3 loops of TCRs interact with antigenic peptides in the T cell ...
  53. [53]
    Large-scale sequence and structural comparisons of human naive ...
    Apr 25, 2016 · Elucidating how antigen exposure and selection shape the human antibody repertoire is fundamental to our understanding of B-cell immunity.
  54. [54]
    Understanding the human antibody repertoire - PubMed Central - NIH
    Within these clones about 9000 unique VDJ rearrangements were seen in the VH sequences, within which 3.4 × 106 unique CDRH3 sequences were found. Of particular ...
  55. [55]
  56. [56]
    Evolution of Adaptive Immune Recognition in Jawless Vertebrates
    All jawed vertebrates assemble their antigen-receptor genes through combinatorial recombination of different “diversity” segments into immunoglobulin or T-cell ...Missing: VNAR | Show results with:VNAR
  57. [57]
    Structure of human IgM rheumatoid factor Fab bound to its ... - Nature
    May 1, 1997 · Rheumatoid factors are the characteristic autoantibodies of rheumatoid arthritis, which bind to the Fc regions of IgG molecules.
  58. [58]
    Structure–function analyses of a stereotypic rheumatoid factor ...
    Rheumatoid factors (RFs) are autoantibodies that specifically recognize the fragment-crystallizable (Fc) region of IgG and have long been used as an important ...
  59. [59]
    Replacing the complementarity-determining regions in a human ...
    May 29, 1986 · The variable domains of an antibody consist of a β-sheet framework with hypervariable regions (or complementarity-determining regions—CDRs) ...
  60. [60]
    Design, expression and characterization of a single chain anti-CD20 ...
    In this study, we humanized the variable domains of Rituximab by CDR grafting method using human germline genes and produced a humanized single chain antibody ...
  61. [61]
    Modeling Immunity with Rosetta: Methods for Antibody and Antigen ...
    Mar 11, 2021 · These tutorials cover antibody structure prediction, docking, and design and antigen design strategies, including the addition of glycans in Rosetta.
  62. [62]
    Atomically accurate de novo design of antibodies with RFdiffusion - Nature
    ### Summary of RFdiffusion for De Novo Antibody Design
  63. [63]
    Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex
    May 1, 2019 · Here we present the cryo-EM structure of HER2-trastuzumab-pertuzumab at 4.36 Å resolution. Comparison with the binary complexes reveals no cooperative ...Missing: CDR2 | Show results with:CDR2
  64. [64]
    Design and engineering of bispecific antibodies - Frontiers
    In this review, we highlight and summarize some of the key considerations in design of bsAbs as well as state-of-the-art engineering principles.
  65. [65]
    Matrixed CDR grafting: A neoclassical framework for antibody ...
    Dec 8, 2023 · This study demonstrates that modern throughput systems enable a more thorough, customizable, and systematic analysis of graft-framework combinations.
  66. [66]
    IgGM: A Generative Model for Functional Antibody and Nanobody Design
    **Summary of IgGM: A Generative Model for Functional Antibody and Nanobody Design**
  67. [67]
    Reprogramming of the heavy-chain CDR3 regions of a human ...
    Jan 5, 2022 · The advent of CRISPR technologies enables ex vivo editing of mature B cells, and adoptive transfer edited B cells into a new murine host.